文献速递肿瘤 PET/CT

铷-82 PET测量肿瘤血流量预测前列腺癌侵袭性:与MRI及钠钾ATP酶密度的关系

Tumour blood flow for prediction of human prostate cancer aggressiveness: a study with Rubidium-82 PET, MRI and Na+/K+-ATPase-density.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2020-08-18

结果显示TBF是MRI引导活检分级分组(GG)的独立预测因子,能区分显著与不显著前列腺癌,但TBF与Na+/K+-ATP酶密度无关。

要点

  • TBF预测GG的效能优于ADC值,且独立于ADC和肿瘤体积。
  • PET区分GG-2-5与GG-1及良性病变的AUC为0.79,灵敏度96%,特异度59%。
  • PET区分GG-3-5与GG-1-2及良性病变的AUC为0.82,灵敏度95%,特异度63%。

核心结论

  • TBF是前列腺癌侵袭性的独立预测因子,有助于区分临床显著与不显著前列腺癌。

研究设计与样本

  • 在MRI上定义肿瘤并转移至82Rb PET测量TBF,随后对活检组织行Na+/K+-ATP酶免疫组化染色。

主要发现

  • TBF与MRI引导活检分级分组(GG)的相关系数rho=0.68(p<0.0001,排除炎性病灶),优于最低ADC值(rho=-0.23,p=0.01)。
  • TBF预测GG独立于ADC值和肿瘤体积(p<0.0001)。
  • PET区分GG-2-5与GG-1及良性病变的AUC、灵敏度、特异度分别为0.79、96%、59%。
  • PET区分GG-3-5与GG-1-2及良性病变的AUC、灵敏度、特异度分别为0.82、95%、63%。
  • 前列腺癌细胞轮廓的Na+/K+-ATP酶密度较良性前列腺细胞轮廓低38%,但细胞密度和Na+/K+-ATP酶密度均未决定肿瘤82Rb摄取。

临床怎么用

  • 82Rb PET测量的TBF可作为无创指标,辅助识别需临床干预的显著前列腺癌。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Tumour blood flow (TBF) is a crucial determinant of cancer growth. Recently, we validated Rubidium-82 (82Rb) positron emission tomography (PET) for TBF measurement in prostate cancer (PCa) and found TBF and cancer aggressiveness positively correlated. The aims of the present study were to determine the ability of TBF for separating significant from insignificant PCa and to examine the relation to underlying Na+/K+-ATPase density, which is relevant as 82Rb is transported intracellularly via the Na+/K+-ATPase. METHODS: One hundred and two patients were included for pelvic 82Rb PET scan prior to magnetic resonance imaging (MRI)-guided prostate biopsy. Findings constituted 100 PCa lesions (86 patients) and 25 benign lesions (16 patients). Tumours were defined on MRI and transferred to 82Rb PET for TBF measurement. Immunohistochemical Na+/K+-ATPase staining was subsequently performed on biopsies. RESULTS: TBF was the superior predictor (rho = 0.68, p < 0.0001, inflammatory lesions excluded) of MRI-guided biopsy grade group (GG) over lowest apparent diffusion coefficient (ADC) value (rho = -0.23, p = 0.01), independent of ADC value and tumour volume (p < 0.0001). PET could separate GG-2-5 from GG-1 and benign lesions with an area under the curve (AUC), sensitivity, and specificity of 0.79, 96%, and 59%, respectively. For separating GG-3-5 from GG-1-2 and benign lesions the AUC, sensitivity, and specificity were 0.82, 95%, and 63%, respectively. Na+/K+-ATPase density per PCa cell profile was 38% lower compared with that of the benign prostate cell profiles. Neither cell density nor Na+/K+-ATPase density determined tumour 82Rb uptake. CONCLUSION: TBF is an independent predictor of PCa aggressiveness and deserves more attention, as it may be valuable in separating clinically significant from insignificant PCa.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Jochumsen MR, Sörensen J, Pedersen BG, et al. Tumour blood flow for prediction of human prostate cancer aggressiveness: a study with Rubidium-82 PET, MRI and Na+/K+-ATPase-density. Eur J Nucl Med Mol Imaging. 2020. PMID: 32808078. doi:10.1007/s00259-020-04998-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。